WO2021054773A1 - Cosmetic composition with multiple emulsion formulation for active ingredient stabilization and skin absorption acceleration - Google Patents

Cosmetic composition with multiple emulsion formulation for active ingredient stabilization and skin absorption acceleration Download PDF

Info

Publication number
WO2021054773A1
WO2021054773A1 PCT/KR2020/012639 KR2020012639W WO2021054773A1 WO 2021054773 A1 WO2021054773 A1 WO 2021054773A1 KR 2020012639 W KR2020012639 W KR 2020012639W WO 2021054773 A1 WO2021054773 A1 WO 2021054773A1
Authority
WO
WIPO (PCT)
Prior art keywords
emulsion
formulation
cosmetic composition
weight
oil phase
Prior art date
Application number
PCT/KR2020/012639
Other languages
French (fr)
Korean (ko)
Inventor
노민주
조영관
오희묵
박현정
김선영
박명삼
이준배
Original Assignee
코스맥스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스맥스 주식회사 filed Critical 코스맥스 주식회사
Publication of WO2021054773A1 publication Critical patent/WO2021054773A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/066—Multiple emulsions, e.g. water-in-oil-in-water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/596—Mixtures of surface active compounds

Definitions

  • It relates to a cosmetic composition of a multi-emulsion formulation for stabilizing active ingredients and promoting absorption.
  • Cosmetics are used on the skin to make the skin beautiful and healthy, and there is an increasing demand for cosmetics containing active substances that help skin whitening or wrinkle improvement.
  • Centella asiatica In the cosmetic industry, Centella asiatica, oleanolic acid, flavonoids, polyphenols, isoflavones, etc. are active ingredients that have a positive effect on the skin, but they do not dissolve well in water, ethanol, oil, or have poor stability, so they are not applied in effective concentrations. There are difficulties that cannot be done.
  • Emulsion refers to a liquid-liquid dispersion system in which one or more immiscible liquid phases are dispersed in another liquid phase, and has various size distributions from tens of nanometers to tens of micrometers.
  • a particle average diameter of 3 to 50 nm is referred to as a microemulsion, 50 to 500 nm, a nanoemulsion, and a 1.5 to 100 ⁇ m macroemulsion.
  • One aspect is to provide a cosmetic composition of a multi-emulsion formulation stabilizing poorly soluble physiological components through double emulsification.
  • Another aspect is to provide a composition for delivery of a physiologically active substance with increased skin absorption of the physiologically active substance to the skin.
  • Another aspect is to provide a method of preparing the composition.
  • One aspect provides a cosmetic composition of multiple emulsion formulations.
  • Another aspect provides a composition for delivery of a physiologically active substance to the skin.
  • the composition comprises a first emulsion of W/O or O/W formulation including an aqueous phase and an oil phase; And a second emulsion of a W/O or O/W formulation including an aqueous phase and an oil phase.
  • the second emulsion when the first emulsion is W/O, the second emulsion may be O/W, or when the first emulsion is O/W, the second emulsion may be W/O.
  • first emulsion or the second emulsion may each contain a second emulsion or a first emulsion or particles thereof (eg, aqueous particles or oil particles).
  • the particles in the first emulsion or the second emulsion may each contain a second emulsion or a first emulsion or particles thereof (eg, aqueous particles or oil particles).
  • the O/W formulation emulsion is present in the W/O aqueous phase particles
  • the first emulsion is an O/W formulation
  • the composition includes a first emulsion of a W/O formulation including an aqueous phase and an oil phase, and a second emulsion of an O/W formulation including an aqueous phase and an oil phase, and the O/W formulation 2
  • Components of the oil phase of the emulsion eg, oil, higher fatty alcohol, surfactant, wax and/or intercellular lipid component
  • the composition may be W/O/W.
  • oil-in-water O/W
  • water-in-water emulsion water-in-oil emulsion
  • non-aqueous dispersion refers to a form dispersed in a solvent other than water.
  • the water-receiving part may be one containing a bioactive material, water, and/or polyol.
  • physiologically active substances may refer to a substance capable of imparting useful activities to an individual, for example, skin regeneration, skin anti-aging, skin wrinkles, skin whitening, and the like.
  • skin throughout the specification, substances that are delivered through the skin (eg, transdermal delivery) to produce a systemic effect may also be included.
  • the physiologically active substances are the first physiologically active substances or the second physiologically active substances, respectively, and the physiologically active substances contained in the first emulsion or the second emulsion may be the same component or different components.
  • Bioactive substances described herein are not limited to low molecular weight drugs, but also include biological compounds such as plant extracts, proteins, peptides, enzymes, DNA, RNA, siRNA, antibodies or fragments thereof, vitamins, minerals or combinations thereof. can do.
  • the reactivating substances used are generally selected from the group consisting of: moisturizing agents, whitening agents, anti-wrinkle agents, sunscreen agents, atopy improving or remedies, acne ameliorating or remedies, antioxidants, analgesics, anti-inflammatory agents, anti-infective agents, wounds or scars. Remedy, burn remedy, nutritional supplements, minerals and vitamins.
  • the physiologically active substance may include a poorly soluble substance.
  • the poorly soluble material may mean a material that is not well soluble or has poor stability in water, ethanol, or oil.
  • solubility The meaning of'poorly soluble' will be described in more detail in terms of solubility as follows. USP/NF generally expresses solubility as the volume of solvent required to dissolve 1 gram of a substance at a specific temperature (eg 1 g of aspirin in 300 ml of H2O, 5 ml of ethanol at 25° C.). Solubility can be described using more subjective terms such as those given in Table 1 below.
  • the term “poorly soluble” in the present specification when using water as a solvent, the lower four solubility categories of Table 1, namely, “inadequate solubility”, “low solubility”, “very low solubility” and " Substantially insoluble or insoluble substances may be included.
  • the poorly soluble substances may include centella asiatica, oleanolic acid, flavonoids, polyphenols, isoflavones, and the like.
  • physiologically active substance examples include Centella asiatica extract or fraction, Asiaticoside, madecassic acid, madecassoside, and madecasic acid. acid) and combinations thereof.
  • the physiologically active substance is 0.1 to 30% by weight, 0.1 to 25% by weight, 0.2 to 25% by weight, 0.2 to 20% by weight, 0.2 to 10% by weight, 0.5 based on the total weight of the emulsion composition (first or second emulsion). It may be included in an amount of to 15% by weight, 0.5 to 20% by weight, 0.2 to 30% by weight, or 0.5 to 10% by weight.
  • water component examples include tap water, mineral water, salt water, sea water, deep ocean water, ultrapure water, polar ice-derived water, mineral-containing water, and purified water. Water is blended in any ratio.
  • polyol and “polyhydric alcohol” are used interchangeably and mean an aliphatic compound having two or more hydroxyl groups (-OH).
  • the polyol may be glycerol, glycol, or a combination thereof.
  • the glycerols may be glycerin, diglycerin, polyglycerin, glycerol, glycyl alcohol, or a combination of two or more thereof.
  • the glycerin may be mixed with other commonly used names such as rislin, propane-1,2,3-triol, 1,2,3-propenetriol, and trihydroxypropane.
  • the glycols are propylene glycol, dipropylene glycol, butylene glycol, diethylene glycol, triethylene glycol, hexylene glycol, pentylene glycol, polyethylene glycol, or It may be a combination of two or more thereof.
  • the polyol is, for example, 0.1 to 50% by weight, 0.1 to 40% by weight, 0.1 to 30% by weight, 0.5 to 30% by weight, 0.5 to 30% by weight, based on the total weight of the emulsion composition (first emulsion or second emulsion) , 0.1 to 20% by weight, 0.1 to 15% by weight, 5 to 40% by weight, 5 to 35% by weight, 15 to 40% by weight, or 15 to 35% by weight. If it is less than 0.1% by weight, it cannot fulfill its role as a base material, and if it is included in more than 50% by weight, formulation stability may not be implemented.
  • the oil phase is a first oil phase containing oil, higher fatty alcohol, wax and/or a surfactant; Alternatively, it may be a second oil phase containing oil, higher fatty alcohol, surfactant, wax and/or intercellular lipid component.
  • the first emulsion or the second emulsion may each include either a first oil phase or a second oil phase. More specifically, one of the first emulsion or the second emulsion may include at least a second oil phase.
  • 'higher fatty alcohol' may mean a monohydric alcohol having 6 or more carbon atoms (eg, C6 to C20).
  • the cosmetic composition it may be an oily raw material in the form of a cream as a high-quality alcohol extracted from natural oil or oil.
  • the higher fatty alcohol is lanolin alcohol, behenyl alcohol (Docosanol), beta-sitosterol, cetyl alcohol, stearyl alcohol, Araki Arachidyl alcohol (Eicosanol), octyl dodecanol, oleyl alcohol, isostearyl alcohol, cholesterol, cetostearyl alcohol, cetearyl alcohol ) Or a mixture thereof.
  • the higher fatty alcohol is 2 to 30% by weight, 2 to 15% by weight, 2 to 20% by weight, 4 to 15% by weight, or It may be 4 to 10% by weight.
  • the wax is not limited as long as it is a wax that can be used in the cosmetic composition, but, for example, fatty acid, vegetable wax, mineral wax, synthetic wax, ozokerite, cetyl palmitate, sorbitan palmitate, bead wax, lipid and lipid It may mean a peptide or the like.
  • Waxes are 0.1 to 10% by weight, 0.1 to 8% by weight, 0.1 to 5% by weight, 0.5 to 5% by weight, 0.2 to 1.5% by weight, 1.8 to 4% based on the total weight of the emulsion composition (first or second emulsion) It may be included in a percentage by weight.
  • the oil may be an ester oil, a hydrocarbon oil, a silicone oil, a vegetable oil, or a mixture thereof.
  • the ester oil of the present invention is C12*?*alkyl octanoate, myristyl lactate, cetyl octanoate, isopropyl myristate, and octyldodecyl Myristate, hexyl laurate, di(C12-C13) alkyl malate, myristyl lactate, octyldodecyl stearoyl Stearate (octyldodecyl stearoyl stearate), diisostearyl malate, pentaerythrityl tetraisostearate or diglyceryl triisostearate.
  • the hydrocarbon-based oil may include hydrogenated, hydrogenated PEG-60 castor oil, hydrogenated polyisobutene, or hydrogenated polydecene.
  • the silicone oil is dimethicone, polydimethylsiloxanes (PDMSs), phenyl trimethicones, phenyl dimethicones, phenyl (trimethylsiloxy) diphenylsiloxane.
  • diphenylsiloxanes diphenyl dimethicones, diphenyl dimethicones, diphenyl(methyldiphenyl)trisiloxanes) or (2-phenylethyl)trimethylsiloxysilicates ), such as phenyl silicones, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, heptamethylhexyltrisiloxane, and heptamethyloctyltrisiloxane.
  • Siloxane (heptamethyloctyltrisiloxane), hexamethyldisiloxane (hexamethyldisiloxane), octamethyltrisiloxane (octamethyltrisiloxane), decamethyltetrasiloxane (decamethyltetrasiloxane) or dodecamethylpentasiloxane (dodecamethylpentasiloxane) may be included.
  • the vegetable oil may include shea butter oil, mango butter oil, cocoa water seed butter oil, macadamia nut oil, olive oil, meadow foam seed oil, refined grape seed oil, peach seed oil, or sunflower seed oil.
  • the oil is 1 to 30% by weight, 2 to 30% by weight, 5 to 30% by weight, 2 to 12% by weight, 2 to 10% by weight, 4 to 12% by weight based on the total weight of the emulsion composition (first or second emulsion) It may be included in a ratio of weight%, 10 to 30% by weight, 12 to 30% by weight, or 12 to 20% by weight.
  • the surfactant is not limited as long as it is a surfactant that can be used in the cosmetic composition, but, for example, polyglycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether Oil, palm oil fatty acid monoethanolamide, polyoxyethylene hydrogenated castor oil, sodium lauryl sulfate, polyoxyethylene glyceryl pyroglutamate isostearic acid, sodium alkylbenzenesulfonate, polyoxyethylene stearyl ether, dialkyl sulfosuccinic acid, cetyl pyridinium bromide , Chloride-n-octadecyltrimethyl ammonium, monoalkyl phosphoric acid, N-acylsultamic acid, N-acyl glutamine, sucrose fatty acid ester, polyoxyethylene sorbitan monostearate, sodium polyoxyethylene
  • the surfactant is 0.1 to 30% by weight, for example, 0.1 to 25% by weight, 0.1 to 20% by weight, 1 to 30% by weight, based on the total weight of the emulsion composition (first emulsion or second emulsion), It may be included in an amount of 1 to 20% by weight, 1 to 5% by weight, 8 to 30% by weight, 8 to 20% by weight, 10 to 30% by weight, 10 to 20% by weight, or 8 to 15% by weight.
  • intracellular lipid may mean a lipid component present between cells of the stratum corneum.
  • the intercellular lipid component may include ceramide, or a derivative thereof, cholesterol or a derivative thereof, a cholesterol ester, a free fatty acid, and the like.
  • ceramide is used interchangeably with N-acylsphingosine, and may include all compounds consisting of sphingosine and fatty acids. Specific examples of the ceramide may include natural ceramide, synthetic ceramide, or a derivative thereof.
  • the ceramide may include one or more selected from the group consisting of ceramide EOP, ceramide NG, ceramide NS, ceramide NP, ceramide AS, and ceramide AP.
  • the ceramide derivative may include a known derivative having properties similar to ceramide.
  • the ceramide or a derivative thereof, or cholesterol or a derivative thereof, a cholesterol ester, or a free fatty acid, respectively, is 0.01 to 5% by weight, for example, 0.01 to 3% by weight, based on the total weight of the emulsion composition (the first emulsion or the second emulsion), 0.05 to 5% by weight, 0.05 to 3% by weight, 0.01 to 2% by weight, 0.01 to 1% by weight, 0.1 to 5% by weight, 0.1 to 3% by weight, 0.1 to 2% by weight, 0.1 to 1% by weight, or 0.05 It may be included in an amount of to 1% by weight.
  • the W/O formulation emulsion is 5 to 50% by weight, 5 to 40% by weight, 5 to 35% by weight, 5 to 30% by weight, 10 to 40% by weight, 10 to It may be included in an amount of 35% by weight, or 10 to 30% by weight.
  • the emulsion of the O/W formulation is 40 to 95% by weight, 50 to 95% by weight, 55 to 90% by weight, 60 to 90% by weight, 50 to 85% by weight, 60 to the total cosmetic composition It may be included in an amount of to 85% by weight, or 55 to 85% by weight.
  • the composition may have piezoelectric properties.
  • the composition may be a piezoelectric composition or a piezoelectric cosmetic.
  • pieelectric composition or “piezoelectric cosmetic” refers to a material capable of generating a microcurrent when pressure is applied, and a physiologically active substance including ceramide or the like is transferred into the skin by such microcurrent ( Transdermal delivery) can be promoted.
  • the piezoelectric constant of the composition may be, for example, 60 to 150 pC, 60 to 120 pC, or 80 to 110 pC.
  • the cosmetic composition according to one embodiment can be prepared in any formulation conventionally prepared in the art.
  • Exemplary product forms include makeup cosmetics such as lipstick, lip gloss, lip cream, and eye shadow; Hair cosmetics such as hair sticks and pomades; Skin, moisturizing gel, moisturizing cream, emulsion, essence, two-stage essence, serum, lotion, cream, liquid foundation, or a basic cosmetic such as a solid foundation formulation, etc. may be mentioned.
  • Another aspect provides a method of preparing a cosmetic composition of multiple emulsion formulations.
  • the method comprises the steps of preparing a first emulsion of a W/O formulation including an aqueous phase and an oil phase; Preparing a second emulsion of an O/W formulation including an aqueous phase and an oil phase; Including the step of preparing a cosmetic composition of a multi-emulsion formulation comprising the step of preparing a mixed solution of a multi-emulsion formulation by adding the second emulsion or the first emulsion to the first emulsion or the second emulsion and then stirring.
  • a cosmetic composition of a multi-emulsion formulation comprising the step of preparing a mixed solution of a multi-emulsion formulation by adding the second emulsion or the first emulsion to the first emulsion or the second emulsion and then stirring.
  • the aqueous phase may be prepared by mixing the components contained in the aqueous phase and dissolving by heating at a temperature of 40 to 80 °C.
  • the oil phase may be prepared by mixing the components contained in the oil phase and dissolving by heating at 60 to 100 °C.
  • the method comprises the steps of mixing a thickener and/or a preservative in the mixed solution; And/or cooling the reactant to at least 40° C. after the stirring, and then removing air bubbles.
  • composition according to an aspect not only is excellent in stabilization of the physiologically active substance in the formulation, there is an effect of improving the absorption of the physiologically active substance in the skin without damaging the skin barrier.
  • FIG. 1 is an optical microscope photograph of Example 1 and Comparative Example 1.
  • FIG. 1 is an optical microscope photograph of Example 1 and Comparative Example 1.
  • Example 2 is a low-temperature scanning electron microscope photograph of Example 1.
  • FIG. 3 is a wide-angle X-ray scattering graph of Example 1 and Comparative Example 1.
  • Figure 4 is a graph showing the in vitro (in vitro) skin absorption effect of Examples 1 and 2.
  • a W/O type emulsion having the composition (unit: weight %) as shown in Table 2 was prepared. Specifically, after weighing each raw material in a beaker according to the ingredients and contents shown in Table 2, the A phase (oil phase) was dissolved by heating at a temperature of 50 to 80°C, and then gradually in the B phase (aqueous phase) at a temperature of 60°C. Put it in. At this time, the mixture of phase A and B was constantly stirred, cooled to 30° C., cooled, and air bubbles were removed to prepare each W/O type emulsion.
  • An O/W type emulsion having the composition (unit: weight %) as shown in Table 3 was prepared. Specifically, after weighing each raw material in a beaker according to the ingredients and contents shown in Table 3, the A phase (oil phase) was dissolved by heating at a temperature of 50 to 80°C, and then gradually in the B phase (aqueous phase) at a temperature of 60°C. Put it in. At this time, the mixture of phase A and B was constantly stirred, cooled to 30° C., cooled, and air bubbles were removed to prepare respective O/W type emulsions.
  • O/W type emulsion ingredient Content (% by weight) Manufacturing Example 2 Manufacturing Example 3 Manufacturing Example 4 A oil 7 7 7 Behenyl alcohol 6 4 6 Pentaerythrityl tetraethylhexanoate 2.5 2.5 2.5 Beeswax 2 2 2 Dimethicone One One One Shea Butter One One One One cholesterol 0.3 0 0.3 Ceramide 0.3 0 0.3 Glyceryl stearate 0.1 0.1 0.1 B Purified water Appropriate amount Appropriate amount Appropriate amount Polyol 10 10 10 Centella Asiatica One 0 0 0
  • each emulsion and raw material are weighed in a beaker according to the components and contents shown in Table 4.
  • part C thickener
  • part D preservative
  • Example 1 A W/O type emulsion: Preparation Example 1 0 20 20 B O/W type emulsion: Preparation Example 2 99 0 0 O/W type emulsion: Preparation Example 3 0 0 79 O/W type emulsion: Preparation Example 4 0 79 0 C Thickener Appropriate amount Appropriate amount Appropriate amount D antiseptic Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount
  • Example 1 In order to find out the properties of the particles of Example 1 and Comparative Example 1, each composition was observed with an optical microscope, and pictures were taken, and are shown in FIG. 1.
  • Figs. 1 and 2 it can be seen that multiple emulsions are formed when a cosmetic composition is prepared by double emulsification by mixing after preparing a W/O type emulsion and an O/W type emulsion.
  • Example 1 a multiphase structure in which the emulsion was present in the emulsion was observed.
  • Comparative Example 1 it was confirmed that no multiphase structure was observed.
  • the moisture feeling refers to the feeling of moisturizing the skin when applied to the skin.
  • Adhesion refers to the feeling that the composition adheres to the skin by applying it to the skin thinly when applied to the skin.
  • Reversal feeling means that the feeling of use is different from when applying the skin for the first time.
  • Example 1 Example 2 Comparative Example 1 Moisture ⁇ ⁇ ⁇ Adhesion ⁇ ⁇ ⁇ Reversal ⁇ ⁇ X Overall satisfaction ⁇ ⁇ ⁇
  • the cosmetic composition having a multi-emulsion structure through double emulsification received high evaluation compared to the general emulsion in adhesion and reversal feeling, and in particular, the cosmetic composition of Example 1 has adhesion and overall satisfaction. Was evaluated higher than in Example 2.
  • the irritation degree of the formulations prepared in Examples 1 to 2 and Comparative Example 1 was evaluated as follows for 20 men and women without skin diseases. After applying 20 ⁇ l of the sample to the entire arm of the testers, the test site was sealed and then applied for 24 hours. 30 minutes and 24 hours after removal of the patch, skin reactions were examined according to the terminology presented in the CTFA guidelines.
  • the skin irritation index (PII) scores of the test subjects obtained according to the criteria were averaged, and if it was less than 1, mild irritation, if it was less than 2, it was evaluated as mild irritation, if it was less than 3.5, it was evaluated as severe irritation.
  • WAXS wide angle X-ray scattering
  • Example 1 the active material was stabilized in the formulation, and only about 1.5 ⁇ -1 peak was observed, indicating the hexagonal packing structure of the emulsion without a precipitation peak. This shows that multiple emulsions through double emulsification can be stably included in the formulation by stabilizing the poorly soluble active material.
  • an artificial film manufactured by Merck Co., Ltd. was placed inside an open glass glass, and after applying an appropriate amount of Examples 1 and 2 on it, respectively, it was sufficiently absorbed. 13 mL of PBS was filled in the acceptor part, and a permeation experiment was conducted at 32°C. After 1, 2, 4, and 8 hours, a portion of the receptor that passed through the artificial membrane was extracted using a PBS solvent, and the concentration of niacinamide was measured through HPLC analysis. HPLC analysis conditions are shown in Table 7 below.
  • Example 4 is a result of evaluating an in vitro skin absorption effect for a cosmetic composition according to an exemplary embodiment.
  • Example 2 not including an intercellular lipid component also exhibited a certain level or higher skin absorption ability.
  • Example 1 In order to evaluate the piezoelectricity of Example 1 and Comparative Example 1, piezoelectric properties were measured using a liquid piezoelectric measuring device (refer to Korean Patent Registration No. 10-1793902).
  • Example 1 and Comparative Example 1 were placed between the electrodes of a liquid piezoelectric measuring device and sampled by moving the motor stage, and then the sample was repeatedly applied with a rotation angle of 10° to apply force. Thereafter, the amount of charge generated by the sample was measured to measure piezoelectric properties, and the results are shown in Table 8 below.
  • Example 1 which is a multi-phase structure, has higher piezoelectricity. Since there are relatively more structures, the movement of molecules is large, so polarization occurs well, and it can be confirmed that piezoelectric properties are high. In addition, this means that the cosmetic composition according to an embodiment can deliver more physiologically active substances.

Abstract

The present invention relates to a cosmetic composition with a multiple emulsion formulation. The composition according to an aspect not only has excellent stabilization of bioactive substances in the formulation, but also an effect of enabling the improvement of skin absorption of bioactive substances without damage to the skin barrier.

Description

활성 성분 안정화 및 피부 흡수 촉진을 위한 다중 에멀젼 제형의 화장료 조성물Cosmetic composition of multi-emulsion formulation for stabilizing active ingredients and promoting skin absorption
활성 성분 안정화 및 흡수 촉진을 위한 다중 에멀젼 제형의 화장료 조성물에 관한 것이다.It relates to a cosmetic composition of a multi-emulsion formulation for stabilizing active ingredients and promoting absorption.
화장품이란 피부를 아름답고 건강하게 하기 위하여 피부에 사용되는 것으로써, 피부 미백이나 주름개선 등에 도움을 주는 활성물질을 포함하는 화장품에 대한 수요가 증가하고 있다.Cosmetics are used on the skin to make the skin beautiful and healthy, and there is an increasing demand for cosmetics containing active substances that help skin whitening or wrinkle improvement.
화장품 산업에서 센텔라아시아티카, 올레아놀릭산, 플라보노이드, 폴리페놀, 이소플라본 등은 피부에 긍정적인 효과를 주는 활성성분이라고 있지만, 물, 에탄올, 오일 등에 잘 녹지 않거나 안정성이 좋지 않아 효과적인 농도로 적용하지 못하는 어려움이 있다.In the cosmetic industry, Centella asiatica, oleanolic acid, flavonoids, polyphenols, isoflavones, etc. are active ingredients that have a positive effect on the skin, but they do not dissolve well in water, ethanol, oil, or have poor stability, so they are not applied in effective concentrations. There are difficulties that cannot be done.
이를 해결하기 위해 난용성 활성물질 안정화 및 흡수 증진을 위해 에멀젼을 이용한다. 에멀젼은 섞이지 않는 하나 이상의 액상이 다른 액상에 분산되어 있는 액-액 분산계를 의미하고, 수십 나노미터에서 수십 마이크로미터의 다양한 크기 분포를 갖는다. 일반적으로 입자 평균 지름이 3 내지 50 ㎚일 경우 마이크로 에멀젼(microemulsion), 50 내지 500㎚일 경우 나노 에멀젼(nanoemulsion), 1.5 내지 100 ㎛일 경우 마크로 에멀젼(macroemulaion)이라 한다.To solve this problem, an emulsion is used to stabilize the poorly soluble active material and improve absorption. Emulsion refers to a liquid-liquid dispersion system in which one or more immiscible liquid phases are dispersed in another liquid phase, and has various size distributions from tens of nanometers to tens of micrometers. In general, a particle average diameter of 3 to 50 nm is referred to as a microemulsion, 50 to 500 nm, a nanoemulsion, and a 1.5 to 100 μm macroemulsion.
그러나, 이러한 에멀젼 내에도 고함량으로 난용성 활성성분을 함유시키거나, 안정성을 증가시기키 어려운 문제점이 있다. 따라서, 난용성 활성성분을 고함량으로 사용할 수 있으면, 안정성을 향상시키고, 이의 피부 흡수를 촉진시킬 수 있는 새로운 제형의 화장료 조성물의 개발이 필요한 실정이다. However, there is a problem in that it is difficult to contain a poorly soluble active ingredient in a high content or to increase stability in such an emulsion. Therefore, if a poorly soluble active ingredient can be used in a high content, there is a need to develop a cosmetic composition of a new formulation capable of improving stability and promoting skin absorption thereof.
일 양상은 이중 유화를 통해 난용성 생리 성분을 안정화한 다중 에멀젼 제형의 화장료 조성물을 제공하는 것이다.One aspect is to provide a cosmetic composition of a multi-emulsion formulation stabilizing poorly soluble physiological components through double emulsification.
다른 양상은 생리활성 물질의 피부 흡수가 증가된 생리활성 물질의 피부로의 전달용 조성물을 제공하는 것이다.Another aspect is to provide a composition for delivery of a physiologically active substance with increased skin absorption of the physiologically active substance to the skin.
또 다른 양상은 상기 조성물을 제조하는 방법을 제공하는 것이다.Another aspect is to provide a method of preparing the composition.
일 양상은 다중 에멀젼 제형의 화장료 조성물을 제공한다. One aspect provides a cosmetic composition of multiple emulsion formulations.
다른 양상은, 생리활성 물질의 피부로의 전달용 조성물을 제공한다.Another aspect provides a composition for delivery of a physiologically active substance to the skin.
상기 조성물은 수상부 및 유상부을 포함하는 W/O 또는 O/W 제형의 제1 에멀젼; 및 수상부 및 유상부을 포함하는 W/O 또는 O/W 제형의 제2 에멀젼을 포함할 수 있다. The composition comprises a first emulsion of W/O or O/W formulation including an aqueous phase and an oil phase; And a second emulsion of a W/O or O/W formulation including an aqueous phase and an oil phase.
또한, 상기 제1 에멀젼이 W/O인 경우, 상기 제2 에멀젼은 O/W이거나, 상기 제1 에멀젼이 O/W인 경우, 상기 제2 에멀젼은 W/O일 수 있다. In addition, when the first emulsion is W/O, the second emulsion may be O/W, or when the first emulsion is O/W, the second emulsion may be W/O.
또한, 상기 제1 에멀젼 또는 제2 에멀젼은 각각 제2 에멀젼 또는 제1 에멀젼 또는 이들의 입자(예를 들면, 수상 입자 또는 유상 입자)를 함유하는 것일 수 있다. 상기 제1 에멀젼 또는 제2 에멀젼 내의 입자는 각각 제2 에멀젼 또는 제1 에멀젼 또는 이들의 입자(예를 들면, 수상 입자 또는 유상 입자)를 함유하는 것일 수 있다. 더욱 상세하게는 상기 제1 에멀젼이 W/O 제형인 경우, 상기 W/O의 수상 입자 내에 O/W 제형의 에멀젼이 존재하는 것이거나, 상기 제1 에멀젼이 O/W 제형인 경우, 상기 O/W의 유상 입자 내에 W/O 제형의 에멀젼이 존재하는 것일 수 있다. In addition, the first emulsion or the second emulsion may each contain a second emulsion or a first emulsion or particles thereof (eg, aqueous particles or oil particles). The particles in the first emulsion or the second emulsion may each contain a second emulsion or a first emulsion or particles thereof (eg, aqueous particles or oil particles). More specifically, when the first emulsion is a W/O formulation, the O/W formulation emulsion is present in the W/O aqueous phase particles, or when the first emulsion is an O/W formulation, the O It may be that the emulsion of the W/O formulation is present in the oily particles of /W.
상세하게는, 상기 조성물은 수상부 및 유상부를 포함하는 W/O 제형의 제1에멀젼, 및 수상부 및 유상부를 포함하는 O/W 제형의 제2 에멀젼을 포함하고, 상기 O/W 제형의 제2 에멀젼의 유상부의 성분(예를 들면, 오일, 고급지방알코올, 계면활성제, 왁스 및/또는 세포간지질 성분)이 상기 W/O 제형의 계면을 감싸면서 형성된 것일 수 있다. 따라서, 상기 조성물은 W/O/W 일 수 있다. In detail, the composition includes a first emulsion of a W/O formulation including an aqueous phase and an oil phase, and a second emulsion of an O/W formulation including an aqueous phase and an oil phase, and the O/W formulation 2 Components of the oil phase of the emulsion (eg, oil, higher fatty alcohol, surfactant, wax and/or intercellular lipid component) may be formed while surrounding the interface of the W/O formulation. Thus, the composition may be W/O/W.
용어, "수중유형 (oil-in-water: O/W)"은 "수중유 에멀젼 (oil-in-water emulsion)"과 상호교환적으로 사용되며, 물에 오일이 분산되어 있는 형태를 의미한다. 용어, "유중수형 (water-in-oil: W/O)"은 "유중수 에멀젼 (water-in-oil emulsion)"과 상호교환적으로 사용되며, 오일에 물이 분산되어 있는 형태를 의미한다. 용어, "비수계 분산형 (non-aqueous dispersion)"은 물이 아닌 용매에 분산되어 있는 형태를 의미한다.The term "oil-in-water (O/W)" is used interchangeably with "oil-in-water emulsion" and refers to a form in which oil is dispersed in water. . The term "water-in-oil (W/O)" is used interchangeably with "water-in-oil emulsion" and refers to a form in which water is dispersed in oil. . The term "non-aqueous dispersion" refers to a form dispersed in a solvent other than water.
본 명세서에서 사용되는 "제1" 또는 "제 2" 등과 같이 서수를 포함하는 용어는 다양한 대상들을 설명하는데 사용할 수 있지만, 상기 대상들은 상기 용어들에 의해 한정되어서는 안 된다. 상기 용어들은 하나의 대상을 다른 대상과 구별하는 목적으로만 사용된다.Terms including ordinal numbers such as "first" or "second" used herein may be used to describe various objects, but the objects should not be limited by the terms. These terms are only used for the purpose of distinguishing one object from another.
상기 수상부는　생리활성 물질, 물, 및/또는 폴리올을 포함하는 것일 수 있다. The water-receiving part may be one containing a bioactive material, water, and/or polyol.
본 명세서에서 용어 "생리활성 물질(physiologically active substances)"은 개체에 유용한 활성, 예를 들면, 피부 재생, 피부 항노화, 피부 주름, 피부 미백 등을 부여할 수 있는 물질을 의미할 수 있다. 본 명세서 전반에 걸처 "피부"에 대하여 언급하고 있지만, 피부를 통해 전달(예를 들면, 경피 전달)되어 전신적인 효과를 내는 물질도 포함할 수 있다. In the present specification, the term "physiologically active substances" may refer to a substance capable of imparting useful activities to an individual, for example, skin regeneration, skin anti-aging, skin wrinkles, skin whitening, and the like. Although reference is made to “skin” throughout the specification, substances that are delivered through the skin (eg, transdermal delivery) to produce a systemic effect may also be included.
생리활성 물질은 제1에멀젼 또는 제2 에멀젼에 포함되는 생리활성 물질은 각각 제1 생리활성 물질 또는 제2 생리활성 물질이고, 이들은 동일한 성분이거나 다른 성분일 수 있다.The physiologically active substances are the first physiologically active substances or the second physiologically active substances, respectively, and the physiologically active substances contained in the first emulsion or the second emulsion may be the same component or different components.
본 명세서에 기술된　생리활성 물질은 저분자　약물에 제한되지 않고, 식물 추출물, 단백질, 펩타이드, 효소, DNA, RNA, siRNA, 항체 또는 이의 단편, 비타민, 미네랄 또는 이들의 조합과 같은 생물학적 화합물을 또한 포함할 수 있다.Bioactive substances described herein are not limited to low molecular weight drugs, but also include biological compounds such as plant extracts, proteins, peptides, enzymes, DNA, RNA, siRNA, antibodies or fragments thereof, vitamins, minerals or combinations thereof. can do.
상기　생리활성 물질의 효과 또는 분포 프로파일을 향상시키기 위하여 다른 화합물 또는 부형제가 첨가될 수 있다.Other compounds or excipients may be added to improve the effect or distribution profile of the 　 bioactive material.
사용되는 리활성 물질은 일반적으로 다음으로 구성된 군으로부터 선택된다: 보습제, 미백제, 주름 개선제, 자외선 차단제, 아토피 개선 또는 치료제, 여드름 개선 또는 치료제, 항산화제, 진통제, 항염증제, 항감염제, 상처 또는 흉터 치료제, 화상 치료제, 영양제, 미네랄 및 비타민.The reactivating substances used are generally selected from the group consisting of: moisturizing agents, whitening agents, anti-wrinkle agents, sunscreen agents, atopy improving or remedies, acne ameliorating or remedies, antioxidants, analgesics, anti-inflammatory agents, anti-infective agents, wounds or scars. Remedy, burn remedy, nutritional supplements, minerals and vitamins.
상기 생리활성 물질은 난용성 물질을 포함할 수 있다. 상기 난용성 물질은 물, 에탄올, 또는 오일에 잘 녹지 않거나 안정성이 좋지 않은 물질을 의미할 수 있다. 상기 '난용성'의 의미를 용해도 기준에서 보다 상세히 설명하면 다음과 같다. USP/NF에서는 일반적으로 1 그램의 물질을 특정 온도에서(예: 1 g의 아스피린을 300 ml의 H2O, 5 ml의 에탄올 중에 25 ℃에서) 용해시키는데 필요한 용매의 용적으로서 용해도를 표현한다. 제시된 하기 표 1에 주어진 것과 같은 보다 주관적인 용어를 사용하여 용해도를 기술할 수 있다.The physiologically active substance may include a poorly soluble substance. The poorly soluble material may mean a material that is not well soluble or has poor stability in water, ethanol, or oil. The meaning of'poorly soluble' will be described in more detail in terms of solubility as follows. USP/NF generally expresses solubility as the volume of solvent required to dissolve 1 gram of a substance at a specific temperature (eg 1 g of aspirin in 300 ml of H2O, 5 ml of ethanol at 25° C.). Solubility can be described using more subjective terms such as those given in Table 1 below.
기술 용어Technical term 1부의 용질 당 필요한 용매의 부Parts of solvent required per part of solute
매우 높은 가용성Very high availability <1<1
높은 가용성 High availability 1 내지 101 to 10
가용성 Availability 10 내지 3010 to 30
불충분한 가용성 Insufficient availability 30 내지 10030 to 100
낮은 가용성Low availability 100 내지 1000100 to 1000
매우 낮은 가용성Very low availability 1000 내지 10,0001000 to 10,000
사실상 불용성 또는 불용성Virtually insoluble or insoluble >10,000>10,000
그러므로, 본 명세서의 용어 "난용성"은, 물을 용매로 사용하는 경우, 상기 표 1의 하위의 4개의 용해도 범주, 즉 "불충분한 가용성", "낮은 가용성", "매우 낮은 가용성" 및 "사실상 불용성 또는 불용성"에 속하는 물질을 포함할 수 있다.상기 난용성 물질의 예는 센텔라아시아티카, 올레아놀릭산, 플라보노이드, 폴리페놀, 또는 이소플라본 등을 포함할 수 있다. Therefore, the term "poorly soluble" in the present specification, when using water as a solvent, the lower four solubility categories of Table 1, namely, "inadequate solubility", "low solubility", "very low solubility" and " Substantially insoluble or insoluble substances may be included. Examples of the poorly soluble substances may include centella asiatica, oleanolic acid, flavonoids, polyphenols, isoflavones, and the like.
일 구체예에 있어서, 상기 생리활성 물질의 구체적인 예는 병풀(Centella asiatica) 추출물 또는 분획물, 아시아티코사이드(Asiaticoside), 마데카인산(madecassic acid), 마데카소시드(madecassoside), 마데카식산(madecasic acid) 및 이들의 조합으로 이루어진 군으로부터 하나를 포함할 수 있다. In one embodiment, specific examples of the physiologically active substance include Centella asiatica extract or fraction, Asiaticoside, madecassic acid, madecassoside, and madecasic acid. acid) and combinations thereof.
상기 생리활성 물질은 에멀젼 조성물(제1 에멀젼 또는 제2 에멀젼) 총 중량 대비 0.1 내지 30 중량%, 0.1 내지 25 중량%, 0.2 내지 25 중량%, 0.2 내지 20 중량%, 0.2 내지 10 중량%, 0.5 내지 15 중량%, 0.5 내지 20 중량%, 0.2 내지 30 중량%, 또는 0.5 내지 10 중량%의 양으로 포함될 수 있다. The physiologically active substance is 0.1 to 30% by weight, 0.1 to 25% by weight, 0.2 to 25% by weight, 0.2 to 20% by weight, 0.2 to 10% by weight, 0.5 based on the total weight of the emulsion composition (first or second emulsion). It may be included in an amount of to 15% by weight, 0.5 to 20% by weight, 0.2 to 30% by weight, or 0.5 to 10% by weight.
물 성분으로서는, 예를 들어, 수돗물, 미네랄 워터, 소금물(salt water), 해수, 해양 심층수, 초순수, 극지 얼음 유래 물, 미네랄 함유수 (mineral-containing water), 정제수 등을 들 수 있다. 물은 임의의 비율로 배합된다.Examples of the water component include tap water, mineral water, salt water, sea water, deep ocean water, ultrapure water, polar ice-derived water, mineral-containing water, and purified water. Water is blended in any ratio.
용어, "폴리올(polyol)", 및 "다가 알콜"은 상호교환적으로 사용되며, 2개 이상의 수산기(-OH)를 가진 지방족 화합물을 의미한다. 상기 폴리올은 글리세롤류, 글라이콜류, 또는 이의 조합일 수 있다. 상기 글리세롤류는 글리세린, 디글리세린, 폴리글리세린, 글리세리톨, 글리실알콜, 또는 이의 2 이상의 조합일 수 있다. 상기 글리세린은 리슬린, 프로판-1,2,3-트리올, 1,2,3-프로페네트리올, 트리히드록시프로판 등 일반적으로 사용되는 다른 명칭과 혼용될 수 있다. 상기 글라이콜류는 프로필렌글라이콜, 디프로필렌글라이콜, 부틸렌글라이콜, 디에틸렌글라이콜, 트리에틸렌글라이콜, 헥실렌글라이콜, 펜틸렌글라이콜, 폴리에틸렌글라이콜, 또는 이의 2 이상의 조합일 수 있다. 상기 폴리올은 예를 들어, 에멀젼 조성물(제1 에멀젼 또는 제2 에멀젼) 총 중량 대비 0.1 내지 50 중량%, 0.1 내지 40 중량%, 0.1 내지 30 중량%, 0.5 내지 30 중량%, 0.5 내지 30 중량%, 0.1 내지 20 중량%, 0.1 내지 15 중량%, 5 내지 40 중량%, 5 내지 35 중량%, 15 내지 40 중량% 또는 15 내지 35 중량%로 포함될 수 있다. 0.1 중량% 미만일 경우 베이스 원료로서의 역할을 다 할 수 없으며, 50 중량% 초과로 포함될 경우 제형 안정성을 구현할 수 없을 수 있다.The terms “polyol”, and “polyhydric alcohol” are used interchangeably and mean an aliphatic compound having two or more hydroxyl groups (-OH). The polyol may be glycerol, glycol, or a combination thereof. The glycerols may be glycerin, diglycerin, polyglycerin, glycerol, glycyl alcohol, or a combination of two or more thereof. The glycerin may be mixed with other commonly used names such as rislin, propane-1,2,3-triol, 1,2,3-propenetriol, and trihydroxypropane. The glycols are propylene glycol, dipropylene glycol, butylene glycol, diethylene glycol, triethylene glycol, hexylene glycol, pentylene glycol, polyethylene glycol, or It may be a combination of two or more thereof. The polyol is, for example, 0.1 to 50% by weight, 0.1 to 40% by weight, 0.1 to 30% by weight, 0.5 to 30% by weight, 0.5 to 30% by weight, based on the total weight of the emulsion composition (first emulsion or second emulsion) , 0.1 to 20% by weight, 0.1 to 15% by weight, 5 to 40% by weight, 5 to 35% by weight, 15 to 40% by weight, or 15 to 35% by weight. If it is less than 0.1% by weight, it cannot fulfill its role as a base material, and if it is included in more than 50% by weight, formulation stability may not be implemented.
상기 유상부는 오일, 고급지방알코올, 왁스 및/또는 계면활성제를 포함하는 제1 유상부이거나; 또는 오일, 고급지방알코올, 계면활성제, 왁스 및/또는 세포간지질 성분을 포함하는 제2 유상부일 수 있다. The oil phase is a first oil phase containing oil, higher fatty alcohol, wax and/or a surfactant; Alternatively, it may be a second oil phase containing oil, higher fatty alcohol, surfactant, wax and/or intercellular lipid component.
상기 제1 에멀젼 또는 제2 에멀젼은 각각 제1 유상부 또는 제2 유상부 중 어느 하나를 포함할 수 있다. 더욱 구체적으로, 상기 제1 에멀젼 또는 제2 에멀젼 중 하나는 적어도 제2 유상을 포함하는 것일 수 있다. The first emulsion or the second emulsion may each include either a first oil phase or a second oil phase. More specifically, one of the first emulsion or the second emulsion may include at least a second oil phase.
본 명세서에서 '고급지방알코올'은 탄소수 6개 이상(예를 들면, C6 내지 C20)의 1가 알코올을 의미할 수 있다. 화장료 조성물에서는 천연 유지나 석유에서 추출되는 고급알코올로 크림형태의 유성 원료일 수 있다. 일 구체예에서, 고급지방알코올은 라놀린알코올(lanolin alcohol), 베헤닐알코올(behenyl alcohol, Docosanol), 베타시토스테롤(beta-sitosterol), 세틸알코올(cetyl alcohol), 스테아릴알코올(stearyl alcohol), 아라키딜알코올(arachidyl alcohol, Eicosanol), 옥틸도데칸올(octyl dodecanol), 올레일알코올(oleyl alcohol), 이소스테아릴알코올(isostearyl alcohol), 콜레스테롤(cholesterol), 세토스테아릴알코올(cetostearyl alcohol, cetearyl alcohol) 또는 이들의 혼합물에서 선택되는 하나인 것일 수 있다. In the present specification,'higher fatty alcohol' may mean a monohydric alcohol having 6 or more carbon atoms (eg, C6 to C20). In the cosmetic composition, it may be an oily raw material in the form of a cream as a high-quality alcohol extracted from natural oil or oil. In one embodiment, the higher fatty alcohol is lanolin alcohol, behenyl alcohol (Docosanol), beta-sitosterol, cetyl alcohol, stearyl alcohol, Araki Arachidyl alcohol (Eicosanol), octyl dodecanol, oleyl alcohol, isostearyl alcohol, cholesterol, cetostearyl alcohol, cetearyl alcohol ) Or a mixture thereof.
본 발명의 일 구체예에서 고급지방알코올은 에멀젼 조성물(제1 에멀젼 또는 제2 에멀젼) 총 중량 대비 2 내지 30 중량%, 2 내지 15 중량%, 2 내지 20 중량%, 4 내지 15 중량%, 또는 4 내지 10 중량%일 수 있다. In one embodiment of the present invention, the higher fatty alcohol is 2 to 30% by weight, 2 to 15% by weight, 2 to 20% by weight, 4 to 15% by weight, or It may be 4 to 10% by weight.
상기 왁스는 화장료 조성물에 사용될 수 있는 왁스류라면 제한이 없으나, 예를 들어, 지방산, 식물성 왁스, 광물성 왁스, 합성 왁스, 오조케라이트, 세틸 팔미테이트, 솔비탄 팔미테이트, 비즈 왁스, 지질 및 지질 펩타이드 등을 의미할 수 있다. 왁스류는 에멀젼 조성물(제1 에멀젼 또는 제2 에멀젼) 총 중량 대비 0.1 내지 10중량%, 0.1 내지 8중량%, 0.1 내지 5중량%, 0.5 내지 5중량%, 0.2 내지 1.5중량%, 1.8 내지 4중량%의 비율로 포함될 수 있다. The wax is not limited as long as it is a wax that can be used in the cosmetic composition, but, for example, fatty acid, vegetable wax, mineral wax, synthetic wax, ozokerite, cetyl palmitate, sorbitan palmitate, bead wax, lipid and lipid It may mean a peptide or the like. Waxes are 0.1 to 10% by weight, 0.1 to 8% by weight, 0.1 to 5% by weight, 0.5 to 5% by weight, 0.2 to 1.5% by weight, 1.8 to 4% based on the total weight of the emulsion composition (first or second emulsion) It may be included in a percentage by weight.
상기 오일은 에스테르계 오일, 하이드로카본계 오일, 실리콘 오일, 식물성 오일 또는 이들의 혼합인 것일 수 있다. 본 발명의 상기 에스테르계 오일은 C12*?*알킬 옥타노에이트(octanoate), 미리스틸 락테이트(myristyl lactate), 세틸 옥타노에이트(cetyl octanoate), 이소프로필 미리스테이트(isopropyl myristate), 옥틸도데실 미리스테이트(octyldodecyl myristate), 헥실 라우레이트(hexyl laurate), 디(C12-C13) 알킬 말레이트(di(C12-C13) alkyl malate), 미리스틸 락테이트(myristyl lactate), 옥틸도데실 스테아로일 스테아레이트(octyldodecyl stearoyl stearate), 디이소테아릴 말레이트(diisostearyl malate), 펜타에리스틸 테트라에틸헥사노에이트(pentaerythrityl tetraisostearate) 또는 디글리세릴 트리이소테아레이트(diglyceryl triisostearate)를 포함할 수 있다. 상기 하이드로카본계 오일은 하이드로제네이티드, 하이드로제네이티드 피이지-60 캐스터오일, 하이드로제네이티드 폴리이소부텐, 또는 하이드로제네이티드폴리데센를 포함할 수 있다. 상기 실리콘 오일은 디메치콘(dimethicone), 폴리디메틸실록산(polydimethylsiloxanes (PDMSs)), 페닐 트리메티콘(phenyl trimethicones), 페닐 디메티콘(phenyl dimethicones), 페닐(트리메틸실록시)디페닐실록산(phenyl(trimethylsiloxy)diphenylsiloxanes), 디페닐 디메티콘(diphenyl dimethicones), 디페닐(메틸디페닐)트리실록산(diphenyl dimethicones, diphenyl(methyldiphenyl)trisiloxanes) 또는 (2-페닐에틸)트리메틸실록시실리케이트((2-phenylethyl)trimethylsiloxysilicates) 같은 페닐실리콘(phenyl silicones), 옥타메틸시클로테트라실록산(octamethylcyclotetrasiloxane),데카메틸시클로펜타실록산(decamethylcyclopentasiloxane),데카메틸시클로헥사실록산(dodecamethylcyclohexasiloxane),헵타메틸헥실트리실록산(heptamethylhexyltrisiloxane),헵타메틸옥틸트리실록산(heptamethyloctyltrisiloxane),헥사메틸디실록산(hexamethyldisiloxane),옥타메틸트리실록산(octamethyltrisiloxane),데카메틸테트라실록산(decamethyltetrasiloxane) 또는 도데카메틸펜타실록산(dodecamethylpentasiloxane)를 포함할 수 있다. 상기 식물성 오일은 쉐어버터 오일, 망고버터 오일, 코코아수씨드 버터 오일, 마카다미아넛오일, 올리브오일, 미도우폼씨드오일, 정제포도씨 오일, 복숭아씨오일, 또는 썬플라워 씨드오일을 포함할 수 있다. 상기 오일은 에멀젼 조성물(제1 에멀젼 또는 제2 에멀젼) 총 중량 대비 1 내지 30중량%, 2 내지 30중량%, 5 내지 30중량%, 2 내지 12중량%, 2 내지 10중량%, 4 내지 12중량%, 10 내지 30중량%, 12 내지 30중량% 또는 12 내지 20중량%의 비율로 포함될 수 있다. The oil may be an ester oil, a hydrocarbon oil, a silicone oil, a vegetable oil, or a mixture thereof. The ester oil of the present invention is C12*?*alkyl octanoate, myristyl lactate, cetyl octanoate, isopropyl myristate, and octyldodecyl Myristate, hexyl laurate, di(C12-C13) alkyl malate, myristyl lactate, octyldodecyl stearoyl Stearate (octyldodecyl stearoyl stearate), diisostearyl malate, pentaerythrityl tetraisostearate or diglyceryl triisostearate. The hydrocarbon-based oil may include hydrogenated, hydrogenated PEG-60 castor oil, hydrogenated polyisobutene, or hydrogenated polydecene. The silicone oil is dimethicone, polydimethylsiloxanes (PDMSs), phenyl trimethicones, phenyl dimethicones, phenyl (trimethylsiloxy) diphenylsiloxane. ) diphenylsiloxanes), diphenyl dimethicones, diphenyl dimethicones, diphenyl(methyldiphenyl)trisiloxanes) or (2-phenylethyl)trimethylsiloxysilicates ), such as phenyl silicones, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, heptamethylhexyltrisiloxane, and heptamethyloctyltrisiloxane. Siloxane (heptamethyloctyltrisiloxane), hexamethyldisiloxane (hexamethyldisiloxane), octamethyltrisiloxane (octamethyltrisiloxane), decamethyltetrasiloxane (decamethyltetrasiloxane) or dodecamethylpentasiloxane (dodecamethylpentasiloxane) may be included. The vegetable oil may include shea butter oil, mango butter oil, cocoa water seed butter oil, macadamia nut oil, olive oil, meadow foam seed oil, refined grape seed oil, peach seed oil, or sunflower seed oil. The oil is 1 to 30% by weight, 2 to 30% by weight, 5 to 30% by weight, 2 to 12% by weight, 2 to 10% by weight, 4 to 12% by weight based on the total weight of the emulsion composition (first or second emulsion) It may be included in a ratio of weight%, 10 to 30% by weight, 12 to 30% by weight, or 12 to 20% by weight.
상기 계면활성제는 화장료 조성물에 사용될 수 있는 계면활성제라면 제한이 없으나, 예를 들어, 폴리글리세린지방산에스테르, 소르비탄지방산에스테르, 폴리옥시에틸렌지방산에스테르, 폴리옥시에틸렌소르비탄지방산에스테르, 폴리옥시에틸렌알킬에테르류, 야자유지방산모노에탄올아미드, 폴리옥시에틸렌 경화 피마자유, 라우릴황산나트륨, 피로글루타민산이소스테아린산폴리옥시에틸렌글리세릴, 알킬벤젠술폰산나트륨, 폴리옥시에틸렌스테아릴에테르, 디알킬술포숙신산, 브롬화세틸피리디늄, 염화-n-옥타데실트리메틸 암모늄, 모노알킬인산, N-아실술타민산, N-아실글루타민, 자당 지방산 에스테르, 폴리옥시에틸렌소르비탄모노스테아레이트, 폴리옥시에틸렌라우릴에테르황산나트륨, 폴리옥시에틸렌 환원 라놀린, 슈거에스테르 및 그의 혼합물로 구성된 군에서 선택된 하나일 수 있다. The surfactant is not limited as long as it is a surfactant that can be used in the cosmetic composition, but, for example, polyglycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether Oil, palm oil fatty acid monoethanolamide, polyoxyethylene hydrogenated castor oil, sodium lauryl sulfate, polyoxyethylene glyceryl pyroglutamate isostearic acid, sodium alkylbenzenesulfonate, polyoxyethylene stearyl ether, dialkyl sulfosuccinic acid, cetyl pyridinium bromide , Chloride-n-octadecyltrimethyl ammonium, monoalkyl phosphoric acid, N-acylsultamic acid, N-acyl glutamine, sucrose fatty acid ester, polyoxyethylene sorbitan monostearate, sodium polyoxyethylene lauryl ether sulfate, polyoxyethylene It may be one selected from the group consisting of reduced lanolin, sugar esters, and mixtures thereof.
일 실시예에서 상기 계면활성제는 에멀젼 조성물(제1 에멀젼 또는 제2 에멀젼) 총 중량 대비 0.1 내지 30 중량%, 예를 들면, 0.1 내지 25 중량%, 0.1 내지 20 중량%, 1 내지 30 중량%, 1 내지 20 중량%, 1 내지 5 중량%, 8 내지 30 중량%, 8 내지 20 중량%, 10 내지 30 중량%, 10 내지 20 중량%, 또는 8 내지 15 중량%의 양으로 포함될 수 있다.In one embodiment, the surfactant is 0.1 to 30% by weight, for example, 0.1 to 25% by weight, 0.1 to 20% by weight, 1 to 30% by weight, based on the total weight of the emulsion composition (first emulsion or second emulsion), It may be included in an amount of 1 to 20% by weight, 1 to 5% by weight, 8 to 30% by weight, 8 to 20% by weight, 10 to 30% by weight, 10 to 20% by weight, or 8 to 15% by weight.
본 명세서에서 용어 "세포간지질성분(Intracellular lipid)"은 각질층의 세포 사이에 존재하는 지질 성분을 의미할 수 있다. 상기 세포간지질성분은 세라마이드, 또는 그의 유도체, 콜레스테롤 또는 그의 유도체, 콜레스테롤 에스테르, 자유지방산 등을 포함할 수 있다. In the present specification, the term "intracellular lipid" may mean a lipid component present between cells of the stratum corneum. The intercellular lipid component may include ceramide, or a derivative thereof, cholesterol or a derivative thereof, a cholesterol ester, a free fatty acid, and the like.
용어 "세라마이드(ceramide)"는 N-아실스핀고신(N-acylsphingosine)와 상호호환적으로 사용되고, 스핑고신과 지방산으로 이루어진 모든 화합물을 포함할 수 있다. 상기 세라마이드의 구체적인 예는 천연 세라마이드, 합성 세라마이드, 또는 그 유도체를 포함할 수 있다. 상기 세라마이드는 세라마이드 EOP, 세라마이드 NG, 세라마이드 NS, 세라마이드 NP, 세라마이드 AS, 및 세라마이드 AP로 이루어진 군으로부터 선택된 하나 이상을 포함할 수 있다. 상기 세라마이드 유도체는 세라마이드와 유사한 성질을 갖는 공지된 유도체를 포함할 수 있다. The term "ceramide" is used interchangeably with N-acylsphingosine, and may include all compounds consisting of sphingosine and fatty acids. Specific examples of the ceramide may include natural ceramide, synthetic ceramide, or a derivative thereof. The ceramide may include one or more selected from the group consisting of ceramide EOP, ceramide NG, ceramide NS, ceramide NP, ceramide AS, and ceramide AP. The ceramide derivative may include a known derivative having properties similar to ceramide.
상기 세라마이드 또는 그의 유도체, 또는 콜레스테롤 또는 그의 유도체, 콜레스테롤 에스테르, 또는 자유지방산 각각은 에멀젼 조성물(제1 에멀젼 또는 제2 에멀젼) 총 중량 대비 0.01 내지 5 중량%, 예를 들면, 0.01 내지 3 중량%, 0.05 내지 5 중량%, 0.05 내지 3 중량%, 0.01 내지 2 중량%, 0.01 내지 1 중량%, 0.1 내지 5 중량%, 0.1 내지 3 중량%, 0.1 내지 2 중량%, 0.1 내지 1 중량%, 또는 0.05 내지 1 중량%의 양으로 포함될 수 있다.The ceramide or a derivative thereof, or cholesterol or a derivative thereof, a cholesterol ester, or a free fatty acid, respectively, is 0.01 to 5% by weight, for example, 0.01 to 3% by weight, based on the total weight of the emulsion composition (the first emulsion or the second emulsion), 0.05 to 5% by weight, 0.05 to 3% by weight, 0.01 to 2% by weight, 0.01 to 1% by weight, 0.1 to 5% by weight, 0.1 to 3% by weight, 0.1 to 2% by weight, 0.1 to 1% by weight, or 0.05 It may be included in an amount of to 1% by weight.
일 구체예에 있어서, 상기 W/O 제형 에멀젼은 전체 화장료 조성물에 대하여 5 내지 50 중량%, 5 내지 40 중량%, 5 내지 35 중량%, 5 내지 30 중량%, 10 내지 40 중량%, 10 내지 35 중량%, 또는 10 내지 30 중량%의 양으로 포함될 수 있다. In one embodiment, the W/O formulation emulsion is 5 to 50% by weight, 5 to 40% by weight, 5 to 35% by weight, 5 to 30% by weight, 10 to 40% by weight, 10 to It may be included in an amount of 35% by weight, or 10 to 30% by weight.
일 구체예에 있어서, 상기 O/W 제형의 에멀젼은 전체 화장료 조성물에 대하여 40 내지 95 중량%, 50 내지 95 중량%, 55 내지 90 중량%, 60 내지 90 중량%, 50 내지 85 중량%, 60 내지 85 중량%, 또는 55 내지 85 중량%의 양으로 포함될 수 있다. In one embodiment, the emulsion of the O/W formulation is 40 to 95% by weight, 50 to 95% by weight, 55 to 90% by weight, 60 to 90% by weight, 50 to 85% by weight, 60 to the total cosmetic composition It may be included in an amount of to 85% by weight, or 55 to 85% by weight.
상기 조성물은 압전 물성을 갖는 것일 수 있다. 상기 조성물은 압전 조성물 또는 압전 화장품일 수 있다. The composition may have piezoelectric properties. The composition may be a piezoelectric composition or a piezoelectric cosmetic.
본 명세서에서 용어 "압전 조성물" 또는 "압전 화장품"은 압력을 가하였을 때 미세전류를 발생시킬 수 있는 물질을 의미하고, 이러한 미세 전류에 의해 세라마이드 등을 포함하는 생리활성 물질이 피부 내로의 전달(경피 전달)이 촉진될 수 있다. In the present specification, the term "piezoelectric composition" or "piezoelectric cosmetic" refers to a material capable of generating a microcurrent when pressure is applied, and a physiologically active substance including ceramide or the like is transferred into the skin by such microcurrent ( Transdermal delivery) can be promoted.
상기 조성물의 압전 상수는 예를 들면, 60 내지 150 pC, 60 내지 120 pC, 또는 80 내지 110 pC 일 수 있다.The piezoelectric constant of the composition may be, for example, 60 to 150 pC, 60 to 120 pC, or 80 to 110 pC.
일 구체예에 따른 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조가 가능하다. 예시적인 제품 형태는 립스틱, 립 글로스, 립 크림, 아이섀도 등의 메이크업 화장료; 헤어 스틱, 포마드 등의 모발 화장료; 스킨, 수분 젤, 수분 크림, 에멀젼, 에센스, 2단계 에센스, 세럼, 로션, 크림, 액상 파운데이션, 또는 고체 파운데이션 제형등의 기초 화장료 등을 예로 들 수 있다.The cosmetic composition according to one embodiment can be prepared in any formulation conventionally prepared in the art. Exemplary product forms include makeup cosmetics such as lipstick, lip gloss, lip cream, and eye shadow; Hair cosmetics such as hair sticks and pomades; Skin, moisturizing gel, moisturizing cream, emulsion, essence, two-stage essence, serum, lotion, cream, liquid foundation, or a basic cosmetic such as a solid foundation formulation, etc. may be mentioned.
또 다른 양상은, 다중 에멀젼 제형의 화장료 조성물을 제조하는 방법을 제공한다. Another aspect provides a method of preparing a cosmetic composition of multiple emulsion formulations.
상기 방법은 수상부 및 유상부를 포함하는 W/O 제형의 제1 에멀젼을 제조하는 단계; 수상부 및 유상부를 포함하는 O/W 제형의 제2 에멀젼을 제조하는 단계; 상기 제1 에멀젼 또는 제2 에멀젼에 대하여 상기 제2 에멀젼 또는 제1 에멀젼을 첨가한 후 교반하여 다중 에멀젼 제형의 혼합용액을 제조하는 단계를 포함하는 다중 에멀젼 제형의 화장료 조성물을 제조하는 단계를 포함할 수 있다. The method comprises the steps of preparing a first emulsion of a W/O formulation including an aqueous phase and an oil phase; Preparing a second emulsion of an O/W formulation including an aqueous phase and an oil phase; Including the step of preparing a cosmetic composition of a multi-emulsion formulation comprising the step of preparing a mixed solution of a multi-emulsion formulation by adding the second emulsion or the first emulsion to the first emulsion or the second emulsion and then stirring. I can.
상기 수상부는 수상 내 함유되는 성분을 혼합하고, 40 내지 80 ℃ 온도에서 가온 용해시켜 제조할 수 있다. The aqueous phase may be prepared by mixing the components contained in the aqueous phase and dissolving by heating at a temperature of 40 to 80 °C.
상기 유상부는 유상 내 함유되는 성분을 혼합하고, 60 내지 100 ℃에서 가온 용해시켜 제조할 수 있다. The oil phase may be prepared by mixing the components contained in the oil phase and dissolving by heating at 60 to 100 °C.
상기 방법은 상기 혼합용액에 점증제 및/또는 방부제를 혼합하는 단계; 및/또는 상기 교반 후 반응물을 적어도 40℃까지 냉각한 후 기포를 제거하는 단계를 더 포함할 수 있다.The method comprises the steps of mixing a thickener and/or a preservative in the mixed solution; And/or cooling the reactant to at least 40° C. after the stirring, and then removing air bubbles.
일 양상에 따른 조성물에 의하면, 생리활성 물질의 제형 내 안정화가 우수할 뿐만 아니라, 피부 장벽의 손상 없이 생리활성 물질의 피부 흡수를 향상시킬 수 있는 효과가 있다.According to the composition according to an aspect, not only is excellent in stabilization of the physiologically active substance in the formulation, there is an effect of improving the absorption of the physiologically active substance in the skin without damaging the skin barrier.
도 1은 실시예 1 및 비교예 1의 광학현미경 사진이다.1 is an optical microscope photograph of Example 1 and Comparative Example 1. FIG.
도 2는 실시예 1의 저온주사전자현미경 사진이다.2 is a low-temperature scanning electron microscope photograph of Example 1.
도 3은 실시예 1 및 비교예 1의 광각 X-선 산란 그래프이다.3 is a wide-angle X-ray scattering graph of Example 1 and Comparative Example 1. FIG.
도 4는 실시예 1 및 2의 인 비트로(in vitro) 피부 흡수 효과를 나타낸 그래프이다.Figure 4 is a graph showing the in vitro (in vitro) skin absorption effect of Examples 1 and 2.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예: 이중 유화를 통한 다중 에멀젼 제형의 화장료 조성물의 제조Example: Preparation of a cosmetic composition of a multi-emulsion formulation through double emulsification
W/O형 에멀젼 제조W/O type emulsion production
하기 표 2와 같은 조성(단위: 중량 %)을 갖는 W/O형 에멀젼을 제조하였다. 구체적으로는 표 2에 기재된 각 성분과 함량에 따라 각 원료를 비이커에 계량한 후 A상(유상부)을 50 내지 80℃ 온도에서 가온 용해 시킨 후, 60℃ 온도인 B상(수상부)에 서서히 투입한다. 이 때, A상과 B상의 혼합물을 일정하게 교반한 후 30℃까지 냉각한 다음, 냉각하고 기포를 제거하여 각각의 W/O형 에멀젼을 제조하였다.A W/O type emulsion having the composition (unit: weight %) as shown in Table 2 was prepared. Specifically, after weighing each raw material in a beaker according to the ingredients and contents shown in Table 2, the A phase (oil phase) was dissolved by heating at a temperature of 50 to 80°C, and then gradually in the B phase (aqueous phase) at a temperature of 60°C. Put it in. At this time, the mixture of phase A and B was constantly stirred, cooled to 30° C., cooled, and air bubbles were removed to prepare each W/O type emulsion.
W/O형 에멀젼W/O type emulsion
성분ingredient 함량 (중량%)Content (% by weight)
제조예 1Manufacturing Example 1
AA 오일oil 1515
트리에칠헥사노인 Triethylhexanoin 55
세틸에칠헥사노에이트 Cetylethylhexanoate 55
폴리글리세릴이소스테아레이트 Polyglycerylisostearate 55
비즈왁스Beeswax 1One
마그네슘스테아레이트Magnesium stearate 0.30.3
BB 정제수Purified water 적량 Appropriate amount
폴리올Polyol 3030
센텔라아시아티카 Centella Asiatica 55
나이아신아마이드 Niacinamide 1010
O/W형 에멀젼 제조O/W type emulsion production
하기 표 3과 같은 조성(단위: 중량 %)을 갖는 O/W형 에멀젼을 제조하였다. 구체적으로는 표 3에 기재된 각 성분과 함량에 따라 각 원료를 비이커에 계량한 후 A상(유상부)을 50 내지 80℃ 온도에서 가온 용해 시킨 후, 60℃ 온도인 B상(수상부)에 서서히 투입한다. 이 때, A상과 B상의 혼합물을 일정하게 교반한 후 30℃까지 냉각한 다음, 냉각하고 기포를 제거하여 각각의 O/W형 에멀젼을 제조하였다.An O/W type emulsion having the composition (unit: weight %) as shown in Table 3 was prepared. Specifically, after weighing each raw material in a beaker according to the ingredients and contents shown in Table 3, the A phase (oil phase) was dissolved by heating at a temperature of 50 to 80°C, and then gradually in the B phase (aqueous phase) at a temperature of 60°C. Put it in. At this time, the mixture of phase A and B was constantly stirred, cooled to 30° C., cooled, and air bubbles were removed to prepare respective O/W type emulsions.
O/W형 에멀젼O/W type emulsion
성분ingredient 함량 (중량%)Content (% by weight)
제조예 2Manufacturing Example 2 제조예 3Manufacturing Example 3 제조예 4Manufacturing Example 4
AA 오일 oil 77 77 77
베헤닐알코올 Behenyl alcohol 66 44 66
펜타에리스리틸테트라에칠헥사노에이트Pentaerythrityl tetraethylhexanoate 2.52.5 2.52.5 2.52.5
비즈왁스 Beeswax 22 22 22
디메치콘Dimethicone 1One 1One 1One
시어버터Shea Butter 1One 1One 1One
콜레스테롤cholesterol 0.30.3 00 0.30.3
세라마이드Ceramide 0.30.3 00 0.30.3
글리세릴스테아레이트Glyceryl stearate 0.10.1 0.10.1 0.10.1
BB 정제수Purified water 적량Appropriate amount 적량Appropriate amount 적량 Appropriate amount
폴리올Polyol 1010 1010 1010
센텔라아시아티카Centella Asiatica 1One 00 00
다중 에멀젼 제조Preparation of multiple emulsions
하기 표 4과 같은 조성(단위: 중량 %)을 갖는 다중 에멀젼을 제조하였다. 구체적으로는 표 4에 기재된 각 성분과 함량에 따라 각 에멀젼 및 원료를 비이커에 계량한다. A상(W/O형 에멀젼)과 B상(O/W형 에멀젼)의 혼합물을 일정하게 교반한 후 C파트(점증제)를 투입하여 교반하고, 30℃까지 냉각한 다음, D파트(방부제)를 투입한다. 그 후 냉각하고 기포를 제거하여 각각의 화장료 조성물을 제조하였다.To prepare a multi-emulsion having the composition (unit: weight %) as shown in Table 4 below. Specifically, each emulsion and raw material are weighed in a beaker according to the components and contents shown in Table 4. After stirring the mixture of A phase (W/O type emulsion) and B phase (O/W type emulsion) constantly, add part C (thickener) to stir, cool to 30°C, and then part D (preservative). ). After that, each cosmetic composition was prepared by cooling and removing air bubbles.
다중 에멀젼Multiple emulsion
성분ingredient 함량(중량%)Content (% by weight)
비교예 1Comparative Example 1 실시예 1Example 1 실시예 2Example 2
AA W/O형 에멀젼: 제조예 1W/O type emulsion: Preparation Example 1 00 2020 2020
BB O/W형 에멀젼: 제조예 2O/W type emulsion: Preparation Example 2 9999 00 00
O/W형 에멀젼: 제조예 3O/W type emulsion: Preparation Example 3 00 00 7979
O/W형 에멀젼: 제조예 4O/W type emulsion: Preparation Example 4 00 7979 00
CC 점증제Thickener 적량Appropriate amount 적량Appropriate amount 적량Appropriate amount
DD 방부제antiseptic 적량Appropriate amount 적량Appropriate amount 적량Appropriate amount
실험예 1: 화장료 조성물 입자 특성 확인Experimental Example 1: Confirmation of cosmetic composition particle characteristics
상기 실시예 1 및 비교예 1의 입자의 특성을 알아보기 위해 광학현미경으로 각 조성물을 관찰하고 사진을 촬영하여 도 1에 나타내었다. In order to find out the properties of the particles of Example 1 and Comparative Example 1, each composition was observed with an optical microscope, and pictures were taken, and are shown in FIG. 1.
도 1 및 도 2에서 나타난 바와 같이, W/O형 에멀젼 및 O/W형 에멀젼 제조 후 혼합함으로써 이중 유화를 화장료 조성물을 제조했을 때 다중 에멀젼이 형성됨을 알 수 있다. 실시예 1에서는 에멀젼 내에 에멀젼이 존재하는 다중상 구조가 관찰되었다. 그러나 비교예 1의 경우는 다중상 구조가 관찰되지 않음을 확인하였다. As shown in Figs. 1 and 2, it can be seen that multiple emulsions are formed when a cosmetic composition is prepared by double emulsification by mixing after preparing a W/O type emulsion and an O/W type emulsion. In Example 1, a multiphase structure in which the emulsion was present in the emulsion was observed. However, in the case of Comparative Example 1, it was confirmed that no multiphase structure was observed.
이와 같은 결과는 이중 유화를 통해 다중상 구조를 가지는 다중 에멀젼을 형성할 수 있다는 점을 시사한다.These results suggest that multiple emulsions having a multiphase structure can be formed through double emulsification.
실험예 2: 사용감 관능 평가Experimental Example 2: Feeling sensory evaluation
상기 실시예 1 내지 2 및 비교예 1의 사용감을 평가하기 위하여 성인 여성 30명을 대상으로, 실시예 1 내지 2 및 비교예 1를 각 군에 적절히 조절하여 얼굴 양쪽 부위에 사용하게 한 후, 하기 평가 기준에 따라 바를 때 느끼는 수분감, 밀착성 및 반전성의 사용감을 평가하였고, 그 결과를 하기 표 5에 나타내었다.In order to evaluate the feeling of use of Examples 1 to 2 and Comparative Example 1, 30 adult women were appropriately adjusted to each group, and Examples 1 to 2 and Comparative Example 1 were appropriately adjusted to be used on both faces, and then the following According to the evaluation criteria, the feeling of moisture, adhesion and reversibility of the feeling of use when applied were evaluated, and the results are shown in Table 5 below.
상기 기준 중 수분감은 피부에 도포 시 피부에 보습을 부여하는 느낌을 말한다. 밀착성은 피부에 도포 시 조성물이 피부 표면에 얇게 발려 피부에 달라붙는 느낌을 말한다. 반전감은 처음 피부 도포시와 바르면서의 사용감이 달라짐을 말한다. 이와 같은 세 가지 기준은 화장료로서의 사용 가치를 높여주며 특히 반전감은 다중상 구조 갖는 화장료의 중요한 특징이 될 수 있다.Among the above criteria, the moisture feeling refers to the feeling of moisturizing the skin when applied to the skin. Adhesion refers to the feeling that the composition adheres to the skin by applying it to the skin thinly when applied to the skin. Reversal feeling means that the feeling of use is different from when applying the skin for the first time. These three criteria increase the value of use as a cosmetic, and in particular, the sense of reversal can be an important feature of a cosmetic with a multiphase structure.
<평가기준><Evaluation Criteria>
24명 이상의 여성이 우수하다고 판정 : ◎More than 24 women judged excellent: ◎
18-23명의 여성이 우수하다고 판정 : ○18-23 women judged excellent: ○
10-17명의 여성이 우수하다고 판정 : △10-17 women judged as excellent: △
10명 이하의 여성이 우수하다고 판정 : X10 or fewer women judged to be excellent: X
실시예 1Example 1 실시예 2Example 2 비교예 1Comparative Example 1
수분감Moisture ○○ ○○ ◎◎
밀착성Adhesion ◎◎ ○○ ○○
반전감Reversal ◎◎ ◎◎ XX
전반적인 만족도Overall satisfaction ◎◎ ○○ △△
상기 표 5에 나타낸 바와 같이, 일 구체예에 따른 이중 유화를 통한 다중 에멀젼 구조의 화장료 조성물은 밀착성 및 반전감에서 일반 에멀젼에 비해 높은 평가를 받았으며, 특히 실시예 1의 화장료 조성물은 밀착성 및 전반적인 만족도에서 실시예 2보다 높은 평가를 받았다. As shown in Table 5, the cosmetic composition having a multi-emulsion structure through double emulsification according to an embodiment received high evaluation compared to the general emulsion in adhesion and reversal feeling, and in particular, the cosmetic composition of Example 1 has adhesion and overall satisfaction. Was evaluated higher than in Example 2.
실험예 3: 피부 안전성 평가Experimental Example 3: Skin safety evaluation
상기 실시예 1 내지 2 및 비교예 1의 피부 안전성 평가를 수행하였다. Skin safety evaluation of Examples 1 to 2 and Comparative Example 1 was performed.
구체적으로, 피부 질환이 없는 성인 남녀 20명을 대상으로 하여 상기 실시예 1 내지 2 및 비교예 1에서 제조된 제형의 자극 정도를 다음과 같이 평가하였다. 시험자들의 팔 전박에 20 ㎕의 시료를 도포한 후, 시험 부위를 밀폐한 후 24시간 동안 첩포하였다. 첩포를 제거한 후 30분과 24시간 후에 피부에서의 반응을 CTFA 가이드라인에 제시된 용어(terminology)에 의거하여 검사하였다. 판정기준에 의해 얻어진 시험자들의 피부자극지수(PII) 점수를 평균하여 1 미만이면 저자극, 2 미만이면 경자극, 3.5 미만이면 중자극, 3.5 이상이면 강자극으로 평가하였다.Specifically, the irritation degree of the formulations prepared in Examples 1 to 2 and Comparative Example 1 was evaluated as follows for 20 men and women without skin diseases. After applying 20 µl of the sample to the entire arm of the testers, the test site was sealed and then applied for 24 hours. 30 minutes and 24 hours after removal of the patch, skin reactions were examined according to the terminology presented in the CTFA guidelines. The skin irritation index (PII) scores of the test subjects obtained according to the criteria were averaged, and if it was less than 1, mild irritation, if it was less than 2, it was evaluated as mild irritation, if it was less than 3.5, it was evaluated as severe irritation.
실험항목Experiment item 실시예 1Example 1 실시예 2Example 2 비교예 1Comparative Example 1
피부자극지수(PII)Skin irritation index (PII) 무자극No irritation 무자극No irritation 무자극No irritation
상기 표 6에 나타낸 바와 같이, 실시예 1 및 2, 및 비교예 1에서 모두 무자극으로 제품에 안전하게 사용 가능함을 확인하였다.As shown in Table 6, it was confirmed that both of Examples 1 and 2 and Comparative Example 1 can be safely used in the product without irritation.
실험예 4: 제형 내 활성물질 안정도 평가Experimental Example 4: Evaluation of the stability of the active substance in the formulation
상기 실시예 1 및 비교예 1의 제형내 활성물질 안정도 평가하기 위하여, 광각 X-선 산란(Wide angle X-ray scattering: WAXS) 분석을 수행하였다. 그 결과를 도 3에 나타내었다.In order to evaluate the stability of the active substance in the formulations of Example 1 and Comparative Example 1, wide angle X-ray scattering (WAXS) analysis was performed. The results are shown in FIG. 3.
도 3에 나타난 바와 같이 비교예 1 조성물의 경우, 에멀젼의 육방정계 패킹 구조를 나타내는 약 1.5 Å-1 피크 (peak)와 결정 피크가 관찰되었다. 이는 난용성 활성물질이 제형 내에서 불안정하여, 결정화되어 석출되었음을 의미한다.As shown in FIG. 3, in the case of the composition of Comparative Example 1, about 1.5 Å -1 peak and crystal peak indicating the hexagonal packing structure of the emulsion were observed. This means that the sparingly soluble active substance is unstable in the formulation and crystallized and precipitated.
이에 반해, 실시예 1 조성물의 경우는 활성물질이 제형 내에서 안정화되어, 석출 피크 없이, 에멀젼의 육방정계 패킹구조를 나타내는 약 1.5 Å-1 피크만 관찰되었다. 이는 이중 유화를 통한 다중 에멀젼이 난용성 활성물질 안정화하여 제형내에 안정하게 포함될 수 있다는 점을 보여준다. On the other hand, in the case of the composition of Example 1, the active material was stabilized in the formulation, and only about 1.5 Å -1 peak was observed, indicating the hexagonal packing structure of the emulsion without a precipitation peak. This shows that multiple emulsions through double emulsification can be stably included in the formulation by stabilizing the poorly soluble active material.
실험예 5: 피부 흡수 효과 확인Experimental Example 5: Confirmation of skin absorption effect
상기 실시예 1 및 2에 대하여 인 비트로(in vitro) 조건에서 수용성 활성물질인 나이아신아마이드의 피부 흡수 효과를 평가하기 위하여 프란츠셀을 사용한 실험을 하였다.For Examples 1 and 2, experiments using Franz Cell were conducted to evaluate the skin absorption effect of niacinamide, a water-soluble active substance, in in vitro conditions.
구체적으로, 오픈된 형태인 유리 초자 내부에 Merck社에서 제조하는 인공막(Strat-M)을 올려두고, 그 위에 실시예 1 및 2를 각각 적량 도포한 후, 충분히 흡수시켰다. 수용체(acceptor) 부분에는 PBS 13mL을 채웠고, 32 ℃에서 투과 실험을 진행하였다. 1, 2, 4, 8시간 경과 후, PBS 용매를 이용하여 인공막을 투과한 수용체 부분을 추출한 후, HPLC 분석을 통해 나이아신아마이드 농도를 측정하였다. HPLC 분석 조건은 하기 표 7과 같다.Specifically, an artificial film (Strat-M) manufactured by Merck Co., Ltd. was placed inside an open glass glass, and after applying an appropriate amount of Examples 1 and 2 on it, respectively, it was sufficiently absorbed. 13 mL of PBS was filled in the acceptor part, and a permeation experiment was conducted at 32°C. After 1, 2, 4, and 8 hours, a portion of the receptor that passed through the artificial membrane was extracted using a PBS solvent, and the concentration of niacinamide was measured through HPLC analysis. HPLC analysis conditions are shown in Table 7 below.
컬럼column C15 (250 ×4.6 ㎜, 5 ㎛, 300 A, Jupiter)C 15 (250 ×4.6 ㎜, 5 ㎛, 300 A, Jupiter)
검출기Detector 역상고압액체크로마토그래피 (Reversed phase high-pressure liquid chromatography; UltiMate 3000, Dionex)Reversed phase high-pressure liquid chromatography (UltiMate 3000, Dionex)
유량 (Flow rate)Flow rate 1.0 ㎖/min1.0 ml/min
흡광도Absorbance 325 ㎚325 nm
이동상Mobile phase 90% 메탄올, 등용매(isocratic) 용리90% methanol, isocratic elution
도 4는 일 구체예에 따른 화장료 조성물에 대한 인 비트로(in vitro) 피부 흡수 효과 평가 결과이다.도 4에 나타낸 바와 같이, 세포간지질 성분을 포함하지 않는 실시예 2도 일정 수준 이상의 피부 흡수능을 나타내었지만, 세포간지질 성분인 콜레스테롤 및 세라마이드를 포함하는 실시예 1이 더 우수한 피부 흡수를 보여주었다. 4 is a result of evaluating an in vitro skin absorption effect for a cosmetic composition according to an exemplary embodiment. As shown in FIG. 4, Example 2 not including an intercellular lipid component also exhibited a certain level or higher skin absorption ability. Although shown, Example 1 containing cholesterol and ceramide, which are intercellular lipid components, showed better skin absorption.
실험예 6: 압전성 테스트Experimental Example 6: Piezoelectricity Test
상기 실시예 1 및 비교예 1의 압전성을 평가하기 위하여 액상 압전 측정 장비(대한민국 등록특허 제10-1793902호 참조)를 이용하여 압전 물성을 측정하였다.In order to evaluate the piezoelectricity of Example 1 and Comparative Example 1, piezoelectric properties were measured using a liquid piezoelectric measuring device (refer to Korean Patent Registration No. 10-1793902).
구체적으로, 각 실시예 1 및 비교예 1 샘플 2 ㎖를 액상 압전 측정 장비의 전극 사이에 넣고 모터 스테이지를 이동시켜 샘플링한 후, 회전각을 10°로 하여 샘플을 반복하여 힘을 가하였다. 이후에, 샘플로 발생한 전하량을 계측하여 압전 물성을 측정하였고, 그 결과를 하기 표 8에 나타내었다. Specifically, 2 ml of each of the samples of Example 1 and Comparative Example 1 were placed between the electrodes of a liquid piezoelectric measuring device and sampled by moving the motor stage, and then the sample was repeatedly applied with a rotation angle of 10° to apply force. Thereafter, the amount of charge generated by the sample was measured to measure piezoelectric properties, and the results are shown in Table 8 below.
실험항목Experiment item 비교예 1Comparative Example 1 실시예 1Example 1
압전 물성 (pC)Piezoelectric properties (pC) 50.4150.41 100.39100.39
그 결과, 표 8에 나타난 바와 같이, 다중상 구조인 실시예 1이 더 높은 압전성을 갖는 것을 확인하였다. 상대적으로 더 많은 구조가 존재하여, 분자의 움직임이 크기 때문에 분극 현상이 잘 일어나 압전 물성이 높음을 확인할 수 있었다. 또한, 이는 일 구체예에 따른 화장료 조성물이 더 생리활성 물질을 잘 전달할 수 있음을 의미한다. As a result, as shown in Table 8, it was confirmed that Example 1, which is a multi-phase structure, has higher piezoelectricity. Since there are relatively more structures, the movement of molecules is large, so polarization occurs well, and it can be confirmed that piezoelectric properties are high. In addition, this means that the cosmetic composition according to an embodiment can deliver more physiologically active substances.

Claims (12)

  1. 수상부 및 유상부을 포함하는 W/O 또는 O/W 제형의 제1 에멀젼; 및 A first emulsion of a W/O or O/W formulation including an aqueous phase and an oil phase; And
    수상부 및 유상부을 포함하는 W/O 또는 O/W 제형의 제2 에멀젼을 포함하고, Including a second emulsion of the W / O or O / W formulation including an aqueous phase and an oil phase,
    상기 제1 에멀젼이 W/O인 경우, 상기 제2 에멀젼은 O/W이거나, 상기 제1 에멀젼이 O/W인 경우, 상기 제2 에멀젼은 W/O이며, When the first emulsion is W/O, the second emulsion is O/W, or when the first emulsion is O/W, the second emulsion is W/O,
    상기 제1 에멀젼 또는 제2 에멀젼은 각각 제2 에멀젼 또는 제1 에멀젼 내의 입자를 함유하는 것인, 다중 에멀젼 제형의 화장료 조성물. The first emulsion or the second emulsion will each contain the particles in the second emulsion or the first emulsion, a cosmetic composition of a multi-emulsion formulation.
  2. 청구항 1에 있어서, 상기 조성물은 수상부 및 유상부를 포함하는 W/O 제형의 제1 에멀젼, 및 수상부 및 유상부를 포함하는 O/W 제형의 제2 에멀젼을 포함하고, 상기 O/W 제형의 제2 에멀젼의 유상부가 상기 W/O 제형의 계면을 감싸면서 형성된 것인, 다중 에멀젼 제형의 화장료 조성물. The method of claim 1, wherein the composition comprises a first emulsion of a W/O formulation including an aqueous phase and an oil phase, and a second emulsion of an O/W formulation including an aqueous phase and an oil phase, The cosmetic composition of the multi-emulsion formulation is formed while the oil phase portion of the second emulsion surrounds the interface of the W / O formulation.
  3. 청구항 1에 있어서, 상기 수상부는 생리활성 물질, 물, 및 폴리올 성분을 함유하는 것인 화장료 조성물. The cosmetic composition of claim 1, wherein the water-receiving part contains a physiologically active substance, water, and a polyol component.
  4. 청구항 1에 있어서, 상기 유상부는 오일, 및 계면활성제를 포함하는 제1 유상부이거나; 또는 오일, 계면활성제, 및 세포간지질 성분을 포함하는 제2 유상부이고, 상기 제1 에멀젼 또는 제2 에멀젼 중 하나는 적어도 제2 유상부를 포함하는 것인 화장료 조성물.The method according to claim 1, wherein the oil phase is a first oil phase containing an oil and a surfactant; Or a second oil phase comprising an oil, a surfactant, and an intercellular lipid component, and one of the first emulsion or the second emulsion comprises at least a second oil phase.
  5. 청구항 4에 있어서, 상기 세포간지질은 세라마이드 또는 그의 유도체, 콜레스테롤, 또는 콜레스테롤 에스테르를 포함하는 것인 화장료 조성물. The cosmetic composition of claim 4, wherein the intercellular lipid contains ceramide or a derivative thereof, cholesterol, or cholesterol ester.
  6. 청구항 5에 있어서, 상기 세라마이드 유도체는 세라마이드 EOP, 세라마이드 NG, 세라마이드 NS, 세라마이드 NP, 세라마이드 AS, 및 세라마이드 AP로 이루어진 군으로부터 선택된 어느 하나인 것인 화장료 조성물. The cosmetic composition of claim 5, wherein the ceramide derivative is any one selected from the group consisting of ceramide EOP, ceramide NG, ceramide NS, ceramide NP, ceramide AS, and ceramide AP.
  7. 청구항 3에 있어서, 상기 생리활성 물질은 병풀(Centella asiatica) 추출물 또는 분획물, 아시아티코사이드(Asiaticoside), 마데카인산(madecassic acid), 마데카소시드(madecassoside), 마데카식산(madecasic acid) 및 이들의 조합으로 이루어진 군으로부터 하나를 포함하는 것인 화장료 조성물. The method of claim 3, wherein the physiologically active substance is Centella asiatica extract or fraction, Asiaticoside, madecassic acid, madecassoside, madecasic acid, and these Cosmetic composition comprising one from the group consisting of a combination of.
  8. 청구항 3에 있어서, 상기 생리활성 물질은 난용성 생리활성 물질인 것인 화장료 조성물. The cosmetic composition according to claim 3, wherein the physiologically active substance is a poorly soluble physiologically active substance.
  9. 청구항 1에 있어서, 상기 W/O 제형 에멀젼은 전체 화장료 조성물에 대하여 5 내지 40 중량%로 포함되고, 상기 O/W 제형의 에멀젼은 전체 화장료 조성물에 대하여 50 내지 95 중량%로 포함되는 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the W/O formulation emulsion is included in an amount of 5 to 40% by weight based on the total cosmetic composition, and the O/W formulation emulsion is included in an amount of 50 to 95% by weight based on the total cosmetic composition. Composition.
  10. 청구항 1에 있어서, 압전 상수가 60 내지 150 pC 인 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the piezoelectric constant is 60 to 150 pC.
  11. 생리활성 물질을 포함하는 수상부 및 유상부를 포함하는 W/O 또는 O/W 제형의 제1 에멀젼; 및 A first emulsion of a W/O or O/W formulation including an aqueous phase and an oil phase including a physiologically active substance; And
    생리활성 물질을 포함하는 수상부 및 유상부를 포함하는 W/O 또는 O/W 제형의 제2 에멀젼을 포함하고, Including a second emulsion of the W / O or O / W formulation including an aqueous phase and an oil phase containing a physiologically active substance,
    상기 제1 에멀젼이 W/O인 경우, 상기 제2 에멀젼은 O/W이거나, 상기 제1 에멀젼이 O/W인 경우, 상기 제2 에멀젼은 W/O이며, When the first emulsion is W/O, the second emulsion is O/W, or when the first emulsion is O/W, the second emulsion is W/O,
    상기 제1 에멀젼 또는 제2 에멀젼 내의 입자는 각각 제2 에멀젼 또는 제1 에멀젼을 함유하는 것인, 생리활성 물질의 피부로의 전달용 조성물. The particles in the first emulsion or the second emulsion each contain a second emulsion or a first emulsion, a composition for delivery of a physiologically active substance to the skin.
  12. 수상부 및 유상부를 포함하는 W/O 제형의 제1 에멀젼을 제조하는 단계; Preparing a first emulsion of a W/O formulation including an aqueous phase and an oil phase;
    수상부 및 유상부를 포함하는 O/W 제형의 제2 에멀젼을 제조하는 단계; 및Preparing a second emulsion of an O/W formulation including an aqueous phase and an oil phase; And
    상기 제1 에멀젼 또는 제2 에멀젼에 대하여 상기 제2 에멀젼 또는 제1 에멀젼을 첨가한 후 교반하여 다중 에멀젼 제형의 혼합용액을 제조하는 단계를 포함하는 다중 에멀젼 제형의 화장료 조성물을 제조하는 단계. The step of preparing a cosmetic composition of a multi-emulsion formulation comprising the step of preparing a mixed solution of a multi-emulsion formulation by adding the second emulsion or the first emulsion to the first emulsion or the second emulsion and then stirring.
PCT/KR2020/012639 2019-09-18 2020-09-18 Cosmetic composition with multiple emulsion formulation for active ingredient stabilization and skin absorption acceleration WO2021054773A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190114958A KR102080459B1 (en) 2019-09-18 2019-09-18 Cosmetic composition having multiple emulsion formulation for stabilizing active ingredient and enhancing the skin penetration
KR10-2019-0114958 2019-09-18

Publications (1)

Publication Number Publication Date
WO2021054773A1 true WO2021054773A1 (en) 2021-03-25

Family

ID=69637431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/012639 WO2021054773A1 (en) 2019-09-18 2020-09-18 Cosmetic composition with multiple emulsion formulation for active ingredient stabilization and skin absorption acceleration

Country Status (2)

Country Link
KR (1) KR102080459B1 (en)
WO (1) WO2021054773A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022251874A1 (en) * 2021-05-28 2022-12-01 Mary Kay Inc. Barrier guard technology

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102080459B1 (en) * 2019-09-18 2020-02-24 코스맥스 주식회사 Cosmetic composition having multiple emulsion formulation for stabilizing active ingredient and enhancing the skin penetration
KR102473474B1 (en) * 2021-12-01 2022-12-02 한국콜마주식회사 Water-in-oil-in-water type emulsion cosmetic composition and method for manufacturing thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520117A (en) * 1997-10-16 2001-10-30 レクサム ソファブ Equipment for assembly of pumps into containers
KR100881298B1 (en) * 2005-09-09 2009-02-03 더 프록터 앤드 갬블 캄파니 Solid skin care composition comprising multiple layers
KR101579063B1 (en) * 2013-09-26 2015-12-21 코스맥스 주식회사 A preparation method of multilamellar liquid crystal emulsions including intercellular lipids
JP6001385B2 (en) * 2012-08-31 2016-10-05 ポーラ化成工業株式会社 Multilayer cream
KR20190024734A (en) * 2017-08-31 2019-03-08 (주)아모레퍼시픽 Cosmetic composition comprising Centella asiatica extract or Triterpene isolated therefrom with high content, and the method for preparing the same
KR102080459B1 (en) * 2019-09-18 2020-02-24 코스맥스 주식회사 Cosmetic composition having multiple emulsion formulation for stabilizing active ingredient and enhancing the skin penetration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935589A (en) * 1997-10-17 1999-08-10 Chesebrough-Pond's Usa Co. Stable cosmetic compositions with different pH emulsions
KR101762011B1 (en) * 2015-09-02 2017-07-26 최화숙 Cosmetic composition capable of triple matrix encapsulation and method for manufacturing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520117A (en) * 1997-10-16 2001-10-30 レクサム ソファブ Equipment for assembly of pumps into containers
KR100881298B1 (en) * 2005-09-09 2009-02-03 더 프록터 앤드 갬블 캄파니 Solid skin care composition comprising multiple layers
JP6001385B2 (en) * 2012-08-31 2016-10-05 ポーラ化成工業株式会社 Multilayer cream
KR101579063B1 (en) * 2013-09-26 2015-12-21 코스맥스 주식회사 A preparation method of multilamellar liquid crystal emulsions including intercellular lipids
KR20190024734A (en) * 2017-08-31 2019-03-08 (주)아모레퍼시픽 Cosmetic composition comprising Centella asiatica extract or Triterpene isolated therefrom with high content, and the method for preparing the same
KR102080459B1 (en) * 2019-09-18 2020-02-24 코스맥스 주식회사 Cosmetic composition having multiple emulsion formulation for stabilizing active ingredient and enhancing the skin penetration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022251874A1 (en) * 2021-05-28 2022-12-01 Mary Kay Inc. Barrier guard technology

Also Published As

Publication number Publication date
KR102080459B1 (en) 2020-02-24

Similar Documents

Publication Publication Date Title
WO2021054773A1 (en) Cosmetic composition with multiple emulsion formulation for active ingredient stabilization and skin absorption acceleration
WO2018044003A1 (en) Oil-in-water type emulsion having excellent stability and cosmetic composition comprising same
JP6884522B2 (en) Topical delivery of skin compositions with low pH
JP4527530B2 (en) Vesicle dispersion and cosmetics containing the same
EP2644188B1 (en) Oil-in-water-type emulsion skin cosmetic
US20030170199A1 (en) Cosmetic and/or dermatological composition based on cocoa extracts
EP1380278A1 (en) Cosmetic emulsion preparation and agent for external use
EP0763354B1 (en) Oil/water mixture composition
WO2016159519A1 (en) Cosmetic composition with multiple emulsion formulation having lamellar liquid crystal structure
BRPI0813092B1 (en) oil-in-water emulsion composition and method for producing it.
MXPA03003585A (en) Complexes of phosphate derivatives.
EP0780116A1 (en) External skin preparation
WO2020022634A1 (en) Liquid crystal emulsion composition for sheet mask, preparation method therefor, and sheet mask comprising same
WO2020105840A1 (en) Composition for stabilizing poorly soluble components and cosmetic composition comprising same
JP2003342195A (en) Inhibitor for parakeratosis, pore reducing agent and external preparation for skin
WO2019245229A1 (en) Cosmetic composition comprising nanoemulsion in which 7-dehydrocholesterol, cholesterol, and stearic acid encapsulated in internal phase of hyaluronic acid-ceramide np complex
AU2004210436A1 (en) Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology
JP2004002289A (en) Parakeratosis inhibitor
WO2015137647A1 (en) Emulsion cosmetic composition without emulsifier
KR102022230B1 (en) Structure of emulsions for enhancing the skin penetration and method of producing the same
WO2018004247A1 (en) Oil-in-water type cosmetic composition comprising high-melting point wax
WO2019045515A1 (en) Oil-in-water type cosmetic composition having stabilized high-content oil inner phase
WO2021049742A1 (en) Cosmetic composition having excellent percutaneous absorption
KR101815127B1 (en) Thermo-sensitive color cosmetic composition and the method of producing the same
WO2021107427A1 (en) Cosmetic composition for skin barrier enhancement or skin bioactive substance absorption promotion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20865272

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20865272

Country of ref document: EP

Kind code of ref document: A1